Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry

Table 4

Univariate and multivariate analyses of baseline characteristics predicting complete disability recovery (HAQ < 0.5).

HAQ < 0.5 (1st year)	Univariate analysis		HAQ < 0.5 (1st year)	Multivariate analysis
	OR (95% CI)	𝑃		OR (95% CI)	𝑃
Age (≥65 versus <65 years)	[0.974 (0.962–0.985)]	<0.0001	Age (≥65 versus <65 years)	[0.978 (0.965–0.99)]	0.0004
Gender (F versus M)	[0.354 (0.248–0.505)]	<0.0001	Gender (F versus M)	[0.417 (0.282–0.617)]	<0.0001
Disease duration (years)	[1.004 (0.985–1.023)]	ns	Disease duration	[0.998 (0.976–1.02)]	ns
DAS28 (high versus moderate versus low)	[0.622 (0.542–0.713)]	<0.0001	DAS28 (high versus moderate versus low)	[0.724 (0.626–0.837)]	<0.0001
DMARDs (no versus yes)	[1.248 (0.724–2.151)]	ns	DMARDs (no versus yes)	[0.85 (0.453–1.596)]	ns
Steroids (no versus yes)	[2.109 (1.445–3.078)]	0.0001	Steroids (no versus yes)	[1.775 (1.153–2.734)]	ns
Adalimumab versus infliximab	[1.495 (1.045–2.138)]	ns	Adalimumab versus infliximab	[1.547 (1.041–2.297)]	0.0307
Etanercept versus infliximab	[1.048 (0.69–1.59)]	ns	Etanercept versus infliximab	[0.871 (0.538–1.41)]	ns
HAQ < 0.5 (5th year)	Univariate analysis		HAQ < 0.5 (5th year)	Univariate analysis
	OR (95% CI)	𝑃		OR (95% CI)	𝑃
Age (≥65 versus <65 years)	[0.978 (0.964–0.991)]	0.0014	Age (≥65 versus <65 years)	[0.982 (0.967–0.996)]	0.0142
Gender (F versus M)	[0.474 (0.31–0.726)]	0.0006	Gender (F versus M)	[0.571 (0.362–0.901)]	0.016
Disease duration	[1.002 (0.979–1.025)]	ns	Disease duration	[0.995 (0.97–1.022)]	ns
DAS28 (high versus moderate versus low)	[0.729 (0.624–0.853)]	0.0001	DAS28 (high versus moderate versus low)	[0.79 (0.668–0.936)]	0.0063
DMARDs (no versus yes)	[0.702 (0.322–1.53)]	ns	DMARDs (no versus yes)	[0.627 (0.255–1.54)]	ns
Steroids (no versus yes)	[1.851 (1.182–2.898)]	0.0071	Steroids (no versus yes)	[1.832 (1.102–3.045)]	0.0195
Adalimumab versus Infliximab	[0.607 (0.383–0.962)]	ns	Adalimumab versus infliximab	[0.554 (0.337–0.911)]	0.0199
Etanercept versus infliximab	[0.607 (0.364–1.011)]	ns	Etanercept versus infliximab	[0.502 (0.284–0.888)]	0.0179

OR: odds ratio; CI: confidence interval; F: female; M: male; DMARDs: disease modifying antirheumatic drugs; DAS28: 28-joint disease activity score; HAQ: Health Assessment Questionnaire.